News

Examination of Inconsistent MDS-UPDRS Ratings in the Parkinson’s Progression Marker Initiative

“Inconsistent Movement Disorders Society-Unified Parkinson’s Disease Rating Scale Part III Ratings in the Parkinson’s Progression Marker Initiative” co-authored by VeraSci expert Dr. Travis Turner was recently published in Movement Disorders. The Parkinson’s Progression Markers Initiative (PPMI) study looked at the ratings of Part III of the Movement Disorders Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) performed by site investigators trained by online training. The study identified likely errors resulting from transcription and data entry and suggests that employing a direct data capture method like eCOA could result in higher quality data.

read more

Dr. Luca Pani Co-authors Article on the Implications of Reimbursement Limits on Patient Access

The European Review for Medical and Pharmacological Sciences recently published “Impact of reimbursement limits on patient access to direct-acting antivirals in Italy: analysis of data from national registries” co-authored by Dr. Luca Pani, VP Regulatory Strategy and Market Access Innovation at VeraSci. The study looked at patients in Italy with Hepatitis C treated with Direct Antiviral Agents (DAA) when Dr. Pani was the Director General of the Italian Medicines Agency (2011-2016) and after that (2017-2018).

read more

Update on VeraSci’s Response to COVID-19

VeraSci is taking all appropriate measures to ensure our staff are prepared to continue business operations over the next several weeks. The governments of the United States and our state of North Carolina have declared a state of emergency and have encouraged...

read more

VeraSci’s Response to COVID-19

We wanted to inform you on VeraSci’s current response and policy formation regarding COVID-19, the coronavirus. VeraSci’s office is currently open. We are taking all appropriate measures to ensure our staff are prepared to continue business operations over the next...

read more